Divide and conquer: using patient-derived tumour organoids to dissect intra-tumour immune heterogeneity of non-small cell lung cancer

Project description

A holistic view on cancer immune evasion

Understanding anti-tumour immunity is central for the design of effective immunotherapy strategies. However, the clonal nature of tumours leads to heterogeneity in treatment response and even drug resistance. Scientists of the EU-funded TxImmuneOrganoids project propose to address this challenge through the development of appropriate patient-derived models. They will establish organoids from non-small cell lung cancer (NSCLC) patients and study their interaction with autologous or allogeneic T cells. Results will provide a holistic and mechanistic overview of immune surveillance and evasion in NSCLC. Moreover, identification of putative molecular determinants may open opportunities for novel anti-cancer interventions.

Fields of science

• natural sciences › biological sciences › genetics › DNA
• medical and health sciences › clinical medicine › oncology › lung cancer
• natural sciences › computer and information sciences › data science › big data
• natural sciences › biological sciences › genetics › mutation
• natural sciences › biological sciences › genetics › RNA

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2020 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2020

See other projects for this call

Funding Scheme

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

Coordinator

THE FRANCIS CRICK INSTITUTE LIMITED

Net EU contribution

€ 224 933,76

Address

1 Midland Road
NW1 1AT London
United Kingdom

Region

London › Inner London — West › Camden and City of London

Activity type

Research Organisations

Links

Other funding

€ 0,00